Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Common Equity (2019 - 2025)

IDEAYA Biosciences (IDYA) has disclosed Common Equity for 7 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • Quarterly Common Equity fell 3.42% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, down 3.42% year-over-year, with the annual reading at $1.0 billion for FY2025, 3.42% down from the prior year.
  • Common Equity hit $1.0 billion in Q4 2025 for IDEAYA Biosciences, down from $1.1 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.2 billion in Q3 2024 to a low of $233.1 million in Q1 2021.
  • Historically, Common Equity has averaged $626.9 million across 5 years, with a median of $504.8 million in 2023.
  • Biggest five-year swings in Common Equity: skyrocketed 180.19% in 2024 and later dropped 7.49% in 2025.
  • Year by year, Common Equity stood at $301.5 million in 2021, then rose by 15.9% to $349.5 million in 2022, then skyrocketed by 77.73% to $621.1 million in 2023, then skyrocketed by 70.53% to $1.1 billion in 2024, then fell by 3.42% to $1.0 billion in 2025.
  • Business Quant data shows Common Equity for IDYA at $1.0 billion in Q4 2025, $1.1 billion in Q3 2025, and $959.7 million in Q2 2025.